At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 229 enrolled
Drug / intervention
ramipril +1 moredrug
Likely dose
ramipril 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo Controlled, Double-Blind Comparative Study Evaluating The Effect of Ramipril On Urinary Protein Excretion In Maintenance Renal Transplant Patients Converted To Sirolimus
In Brief
A Phase 4 clinical trial evaluating ramipril for Kidney Transplant. Completed, enrolled 229 participants across 49 sites in 12 countries.
Detailed Summary
The primary objective of the study is to determine the efficacy of ramipril in preventing a urinary protein to creatinine ratio (U p/c) greater than 0.5 following conversion to sirolimus from a calcineurin inhibitor (CNI) in maintenance kidney transplant patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Transplant
CountriesArgentina, Australia, Austria, Brazil, Canada, Germany, Hungary, Israel, Mexico, Poland, South Africa, United States
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2007
Enrollment StartDec 2007
Primary CompletionSep 2013
TodayJul 2026
First PostedJul 17, 2007
Enrollment StartDec 1, 2007
Primary CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 19.0 years ago
Interventions
ramiprildrug
Capsule - initial treatment is 5 mg (active)- oral - once per day
ramiprildrug
Capsule - initial treatment is 5 mg (placebo) - oral - once per day